{
  "id": "5a7d54adfaa1ab7d2e000019",
  "type": "yesno",
  "question": "Has IVIG been tested in clinical trials for the treatment of Alzheimer's disease?",
  "ideal_answer": "Yes, IVIG has been tested in clinical trials for the treatment of Alzheimer's disease.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/24760112"
  ],
  "snippets": [
    {
      "text": "Clinical trials of intravenous immunoglobulin for Alzheimer's disease.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/24760112",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Preclinical and clinical studies have shown that IVIG has anti-amyloid and immune modulatory properties relevant to treating neurodegenerative disorders. In early stage AD clinical trials, IVIG was found to reduce cognitive decline and increase brain glucose metabolism. Unfortunately, IVIG failed to meet primary outcome objectives in the North American Phase 3 clinical trial in mild to moderate AD.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/24760112",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "While the results of clinical trials to date do not provide support for the use of IVIG to treat AD at the doses tested, additional studies of IVIG's mechanisms are warranted and may guide the development of more effective therapies for AD in the future.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/24760112",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": [],
  "exact_answer": "Yes"
}